A Catastrophic Antiphospholipid Syndrome Case With Poor Prognosis Criteria Improved With Early Diagnosis and Effective Treatment

Author(s):  
Savas Volkan Kisioglu
2008 ◽  
Vol 248 (6) ◽  
pp. 519-524
Author(s):  
E. G. Zakynthinos ◽  
T. Vassilakopoulos ◽  
D. D. Kontogianni ◽  
C. Roussos ◽  
S. G. Zakynthinos

2000 ◽  
Vol 248 (6) ◽  
pp. 519-524 ◽  
Author(s):  
E. G. Zakynthinos ◽  
T. Vassilakopoulos ◽  
D. D. Kontogianni ◽  
C. Roussos ◽  
S. G. Zakynthinos

2019 ◽  
Vol 12 (9) ◽  
pp. e230863 ◽  
Author(s):  
Mandy Collict ◽  
Whitney Sciberras Buhagiar ◽  
Cecilia Mercieca ◽  
John Thake

Catastrophic antiphospholipid syndrome (CAPS) is a rare and potentially life-threatening variant of the antiphospholipid syndrome which is characterised by multiple small vessel thrombosis which can lead to multiorgan failure. CAPS is a clinical emergency which all clinicians need to be aware of because early diagnosis and treatment may improve maternal and fetal outcome. Here, we report a case of CAPS in pregnancy in a 31-year-old female patient who presented at 28 weeks of gestation. A literature review of CAPS in pregnancy and the puerperium is also included.


Vestnik ◽  
2021 ◽  
pp. 341-344
Author(s):  
М.А. Жанузаков ◽  
М.К. Бапаева ◽  
Г.К. Джалилова ◽  
А.Ж. Шурина ◽  
Э.М. Утежанов

Клинические проявления катастрофического антифосфолипидного синдрома многообразны, что затрудняет своевременную диагностику и соответственно адекватное лечение. Цель: устранить трудности, возникающие у практических врачей при постановке диагноза, дифференциальной диагностике и лечении катастрофического антифосфолипидного синдрома, основываясь на анализе данных литературы и на примере клинического случая. Материалы и методы: исследований по данной проблеме в отечественных источниках мы не встретили, что привело к необходимости остановиться на литературных данных и клиническом примере. Результаты: на основании анамнеза заболевания, результатов клинического и дополнительных методов исследования пациента, установлен диагноз катастрофического антифосфолипидного синдрома. Выводы: для ранней диагностики катастрофического антифосфолипидного синдрома необходима настороженность при возникновении признаков ДВС-синдрома и быстро развивающейся полиорганной недостаточности. Clinical manifestations of the catastrophic antiphospholipid syndrome are diverse, which complicates timely diagnosis and, accordingly, adequate treatment. Goal: eliminate the difficulties encountered by practitioners in the diagnosis, differential diagnosis and treatment of catastrophic antiphospholipid syndrome, based on the analysis of literature data and on the example of a clinical case. Materials and methods: we did not find any studies on this issue in domestic sources, which led to the need to focus on literature data and a clinical example. Results: on the basis of the anamnesis of the disease, the results of clinical and additional research methods of the patient, a diagnosis of catastrophic antiphospholipid syndrome was established. Conclusions: for early diagnosis of catastrophic antiphospholipid syndrome, alertness is required when signs of disseminated intravascular coagulation and rapidly developing multiple organ failure occur.


2019 ◽  
Author(s):  
De Marchi Lucrezia ◽  
M K de Filette Jeroen ◽  
Sol Bastiaan ◽  
E Andreescu Corina ◽  
Kunda Rastislav ◽  
...  

2021 ◽  
pp. 1-10
Author(s):  
Zhongyin Yang ◽  
Chao Yan ◽  
Wentao Liu ◽  
Wei Xu ◽  
Chen Li ◽  
...  

BACKGROUND: Gastric cancer (GC) patients with peritoneal metastasis usually have extremely poor prognosis. Intraperitoneal infusion of paclitaxel (PTX) provides an effective treatment, but relapse and PTX-resistance are unavoidable disadvantages, and it is difficult to monitor the occurrence of PTX-resistance. OBJECTIVE: The aim of this study was to explore novel autoantibodies in the ascites of individuals with relapsed PTX-resistant GC with peritoneal metastasis. METHODS: Ascites samples were collected before PTX infusion and after the relapse in 3 GC patients. To determine the expression of significantly changed proteins, we performed autoantibody profiling with immunome protein microarrays and tandem mass tag (TMT) quantitative proteomics, and then, the overlapping proteins were selected. RESULTS: Thirty-eight autoantibodies that were differentially expressed between the ascites in the untreated group and relapsed PTX-resistant group were identified. For confirmation of the results, TMT quantitative proteomics was performed, and 842 dysregulated proteins were identified. Four proteins, TPM3, EFHD2, KRT19 and vimentin, overlapped between these two assays. CONCLUSIONS: Our results first revealed that TPM3, EFHD2, KRT19 and vimentin were novel autoantibodies in the ascites of relapsed PTX-resistant GC patients. These autoantibodies may be used as potential biomarkers to monitor the occurrence of PTX-resistance.


Lupus ◽  
2001 ◽  
Vol 10 (5) ◽  
pp. 382-383
Author(s):  
F J Wiedermann ◽  
W Lederer ◽  
N Sepp ◽  
W Schobersberger

Sign in / Sign up

Export Citation Format

Share Document